Publications by authors named "V Garcia-Gutierrez"
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Virginia Escamilla-Gómez Valentín García Gutiérrez Patricia Alcalde-Mellado Beatriz Astibia-Mahillo Anabelle Chinea-Rodriguez
Bone Marrow Transplant
December 2024
Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD.
View Article and Find Full Text PDFArticle Synopsis
- Ponatinib and asciminib are both approved for treating chronic-phase chronic myeloid leukemia (CP-CML) in the U.S., specifically for patients who have not responded to other therapies or have the T315I mutation, with ponatinib also available in Europe for this mutation.
- A systematic review identified clinical trials comparing the effectiveness of ponatinib and asciminib for patients who have relapsed or are resistant to treatments, and a statistical analysis was used to compare their response rates after matching patient characteristics.
- Results showed ponatinib had significantly higher response rates than asciminib, particularly in patients with the T315I mutation, indicating that ponatinib may be a more effective treatment option in these cases.
Article Synopsis
- - HIV-1 infection persists due to long-term viral reservoirs in latently infected CD4 T cells, prompting the need for strategies to stimulate cytotoxic immunity, including the "Shock and Kill" approach.
- - Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, has shown effectiveness against HIV-1 and may enhance the immune response against both cancer and viral infections.
- - In a study of patients with chronic myeloid leukemia who switched from imatinib to ponatinib, results indicated that ponatinib treatment significantly reduced HIV-1 infection rates and increased the cytotoxic response from peripheral blood mononuclear cells, with effects lasting at least 12 months post-treatment.
Article Synopsis
- Hydroxyurea (HU) is the primary treatment for essential thrombocythemia (ET), but there are no clear guidelines for when to switch therapies.
- In a study of 1080 patients, 67% achieved a complete hematological response (CHR) after five years, with high-risk patients showing lower risks of arterial thrombosis if they achieved CHR.
- Patients with HU resistance or intolerance had a higher chance of developing myelofibrosis, but this did not significantly impact overall survival or thrombotic risk; CHR is linked to improved outcomes and may guide future treatment decisions.
Article Synopsis
- * Out of these patients, 8 experienced treatment intolerance with asciminib while 11 developed resistance; treatment strategies included dose adjustments of cTKIs or considering ponatinib despite previous non-candidacy.
- * The overall survival rate was 73% with the best outcomes for those intolerant to drugs (100%), while patients who progressed to advanced stages had a notably low survival rate (25%).